Company intelligence / Profile preview

BioCellgraft

New York, New York, United Statesprweb.com ↗

Ownership: Private
Development stage: Commercial

Overview

BioCellgraft has developed regenerative therapies for oral healthcare using Human Connective Tissue Matrix (HCTM). Their products began to be made available to select practitioners and patients in Q2 2024, with injectable therapeutics and regenerative scaffold sheets designed to enhance healing and tissue strength in oro-facial procedures[1][3].

Therapeutic areas: OtherEndocrinologyDermatology
Modalities: Human Connective Tissue Matrix (HCTM)placental-derived biomaterial products
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Orafyl

Commercial

Indications: Soft tissue regeneration, Periodontal applications, Dental implant procedures

Partnerships

Celularity Inc. (Nasdaq: CELU)

Beyond the preview

Go deeper on BioCellgraft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCellgraft.

Explore the full profile